

Review

# Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

Angelica Ferrando-Díez<sup>1,2†</sup>, Eudald Felip<sup>1,2,3†</sup>, Anna Pous<sup>1,2</sup>, Milana Bergamino Sirven<sup>1,2\*</sup> and Mireia Margelí<sup>1,2\*</sup>

<sup>1</sup> Medical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol (HGTTiP), 08916 Badalona, Spain

<sup>2</sup> (B-ARGO) Badalona Applied Research Group in Oncology, (IGTP), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Departament de Medicina, Universitat Autònoma de Barcelona, 08916 Badalona, Spain

<sup>3</sup> AIDS Research Institute-IrsiCaixa, IGTP (Health Research Institute Germans Trias i Pujol), Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain

\* Correspondence: mbergamino@iconcologia.net (M.B.); mmargeli@iconcologia.net (M.M) Tel.: +34-93-497-8925 (M.B. & M.M.)

† Authors to whom correspondence should be addressed.

† These authors contributed equally to this work.

**Simple Summary:** The development of several Anti-Human Epidermal Growth Factor Receptor (HER2) treatments over the last few years has improved the landscape of HER2-positive breast cancer. Despite this, relapse is still a main issue in HER2-positive breast cancer. The reasons for therapeutic failure lie in the heterogeneity of the disease itself, as well as in the drug resistance mechanisms. In this review, we intended to understand the milestones that have had an impact on this disease up to their implementation in clinical practice. In addition, understanding the underlying molecular biology of HER2-positive disease is essential for the optimization and personalization of the different treatment options. For this reason, we focused on two relevant aspects, which are triple-positive disease and the role that modulation of the immune response might play in treatment and prognosis.

**Abstract:** Up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse despite the improvement achieved by the introduction of HER2-targeted therapy. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T-DM1) and the reversible HER2 inhibitor lapatinib. New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown an improvement in the metastatic setting. Other therapeutic strategies to overcome treatment resistance have been explored in HER2+ BC, mainly in HER2+ that also overexpress estrogen receptors (ER+). One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6) as they are downstream of HER2 and many of the cellular pathways associated with resistance to HER2-targeted therapies play a key role in cell cycle and proliferation. Different trials have explored these strategies with encouraging results, but definitive results are needed. In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors. Different immunotherapeutic agents have been investigated in this setting, with promising but controversial results obtained to date.

**Keywords:** breast cancer; HER2-positive; estrogen receptor positive; triple-positive; HER2-targeted therapy; immunotherapy

## 1. HER2-targeted therapy

### 1.1. Introduction

Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast carcinomas (1-3). HER2-positive (HER2+) breast cancer (BC) is a heterogeneous and aggressive disease. Despite the dramatic improvement after the introduction of HER2-targeted therapy (4-6), 15-25% of patients in the early stage will still relapse (4, 5, 7, 8). Endocrine receptor status and intrinsic molecular subtypes play a key role in determining response to anti-HER2 treatment, as reported in several neoadjuvant studies (9). However, they do not fully recapitulate tumor heterogeneity and other biological features have been associated with response heterogeneity to HER2-targeted therapy and the risk of relapse. In recent years, research has focused on developing novel drugs, including anti-HER2 therapies with alternative and optimized mechanisms of action and others targeting new potential pathways to prevent and overcome resistance.

In the neoadjuvant setting, dual HER2-blockade has significantly improved the pathologic complete response (pCR) rate, a potential surrogate endpoint of improved survival, with ranges of 40-65%, depending on the treatment regimens and duration of neoadjuvant treatment (1, 8). Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T-DM1) and the reversible HER2 inhibitor lapatinib. Dual HER2-blockade administered in combination with chemotherapy has improved the survival of patients with metastatic BC. Beyond these, new agents have also shown improved progression-free survival (PFS) and overall survival (OS) in the metastatic setting, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab (10, 11).

Beyond the HER2 receptor, other therapies to overcome treatment resistance are being actively investigated in HER2+ BC. One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6) as they are downstream of HER2 and many of the cellular pathways associated with resistance to HER2-targeted therapies play a key role in cell cycle and proliferation. Different trials have explored these strategies with encouraging and promising results, but definitive results are needed (12, 13).

In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors; thus, different immunotherapeutic agents are under investigation in this setting, with controversial results obtained to date (14, 15).

This review reports the current and new therapeutic approaches being explored in HER2+ BC.

## 2. HER2-positive disease – current approaches

Several treatment options for HER2+ BC patients are now available for both early and metastatic disease, improving the prognosis of this BC type.

Passive immunotherapy with HER2-directed monoclonal antibodies (mAbs), such as trastuzumab and pertuzumab, in combination with chemotherapy leads to the downregulation of the oncogenic intracellular pathways triggered by HER2 activation via homo- and hetero-dimerization in the cancer cell membrane (16). Combining these two agents has shown synergy due to the relevant interactions between them and the immune system, leading to antibody-dependent cellular toxicity (17).

On the other hand, in recent years, HER2-directed ADCs such as T-DM1 or Trastuzumab-deruxtecan (T-DXd) have been developed to produce an increased cytotoxic effect in target cells and reduce target side effects (6). These agents are molecules formed by an antibody linked to a chemotherapeutic agent, showing high efficacy due to the inherent activity of both the antibody and the chemotherapeutic agent but also, and especially in the case of new ADCs such as T-DXd, because they have an immune-modulator effect that affects neighboring cells (18, 19).

Other options for HER2+ BC patients include small-molecule tyrosine kinase inhibitors (TKI) such as lapatinib, neratinib and tucatinib. Lapatinib is an orally bioavailable reversible inhibitor of the epidermal growth factor receptor (EGFR) and HER2 that blocks

phosphorylation of tyrosine kinase residues, thus inhibiting cell proliferation by blocking the MAPK and PIK3 pathways (20). Neratinib, another irreversible inhibitor of EGFR, HER2 and HER4 (21), has been proven to induce cell cycle arrest and decrease HER2+ cell proliferation in preclinical studies (21). Tucatinib is a highly selective and reversible HER2 inhibitor that potently inhibits signal transduction downstream of HER2 and HER3 via the MAPK and PI3K/AKT pathways (22). Some studies reported that patients who progress after trastuzumab could benefit from a TKI with or without trastuzumab (11, 23). This benefit may be caused by the different mechanisms of action and targets within the HER2 receptor, which allows the TKI to overcome trastuzumab resistance (24-26).

### 2.1. HER2-positive early breast cancer – current approaches.

As explained above, the recent incorporation of several new therapies in recent years has improved the prognosis of HER2+ early breast cancer (EBC); however, up to 25% of EBC patients will still relapse; thus, there are many opportunities for improvement in this setting.

#### 2.1.1. De-escalation approaches in the early setting

The pivotal HERA, BCIRG-006, NSABP B-31 and NCCTG N9831 trial results (27-30) established one year of trastuzumab (H) combined with three to six months of chemotherapy as the current standard adjuvant treatment for HER2+ EBC. The HERA trial showed no additional benefit after one year of targeted therapy (31). Some strategies to avoid over-treatment of HER2+ patients have evaluated a shorter anti-HER2 adjuvant treatment. The Short-HER and SOLD trials evaluated nine weeks versus one year of H (32, 33). Non-inferiority of one-year treatment over the nine-week course was not demonstrated for disease-free survival (DFS) in any of these studies. The Short-HER trial showed favorable DFS (8.7 years of follow-up) in patients at low or intermediate risk of relapse in a *post hoc* analysis (34). The PHARE trial also failed to demonstrate non-inferiority of 6 versus 12 months of H (35). Finally, the phase III PERSEPHONE trial compared 6 versus 12 months of H and met its primary endpoint of non-inferiority in terms of DFS at four years. Nevertheless, OS results favored 12 months of H (36).

Some trials evaluated the de-escalation of chemotherapy strategies. Examples are the schedules without anthracyclines, such as the APT trial assessing the combination of 12 weeks of adjuvant paclitaxel with H for 12 months in patients with  $\leq 3$  cm, node-negative tumors (37). The seven-year rates for invasive DFS (iDFS) of 93% and OS of 95% provided evidence to de-escalate chemotherapy in low-risk patients. The neoadjuvant scenario is a common strategy in HER2+ EBC. pCR correlates with patient outcomes and allows us to select subsequent therapies (38). The TRAIN-2 study tested the use of anthracycline and non-anthracycline chemotherapy combined with pertuzumab (P) and H; no differences were obtained in pCR rates, three-year event-free survival (EFS) and OS (39, 40). The WSG-ADAPT trial evaluated dual HER2 blockade with P, with or without 12 weeks of paclitaxel. In the hormone receptor (HR) negative patients, the pCR rate was 90.5% with chemotherapy (41). In addition, the KRISTINE trial compared T-DM1 plus P with Docetaxel (T), C (Carboplatin) plus HP, showing a lower pCR rate and higher risk of locoregional progression events with T-DM1 (42, 43).

Furthermore, some trials explored the efficacy of chemotherapy-free combinations; TBCRC006/023, PER-ELISA and SOLTI-PAMELA achieved a 30% pCR rate with dual blockade with lapatinib (L) in combination with H but without chemotherapy (44, 45). The analysis of the intrinsic subtypes in the PAMELA trial provided pCR rates of 41% for the HER2-enriched (HER2-E) subtype. In contrast, in the NeoSphere trial, a 16.8% pCR rate was achieved in the H plus P without chemotherapy arm (46). The PHERGain trial explored whether omitting chemotherapy in PET (Positron Emission Tomography) responders was feasible. After two cycles of P and H, eight cycles were administered prior to surgery in patients with response according to PET and six cycles of TCHP in non-

responders. Eighty percent of patients in the HP arm were responders and were spared chemotherapy, 40% of which achieved pCR (47).

### 2.1.2. Escalation approaches in HER2-positive EBC

The intensification of therapy using dual anti-HER2 blockade has been another strategy in HER2+ EBC. The APHINITY trial randomized 4800 patients to receive adjuvant chemotherapy plus H with or without P for 12 months. Results showed a statistically significant but marginal benefit in terms of three-year iDFS, especially in node-positive patients, thus it is not routinely used (48). Adjuvant dual blockade with chemotherapy in combination with L plus H was also tested, showing no improvement in outcome and presenting increased toxicity (49).

In the neoadjuvant setting, different intensification schemes have been tested. The KAITLIN trial evaluated the combination of T-DM1 plus P compared with taxane plus HP after anthracycline-based therapy in very high-risk patients. The results failed to find a reduction in the risk of invasive disease in the experimental arm (50). The NeoSphere phase II trial evaluated dual blockade, randomizing patients to receive four neoadjuvant cycles of HT, PHT, PH or HT. This trial reported a higher pCR with dual blockade plus T than with HT, with no additional cardiotoxicity in arms with dual HER2 blockade. Furthermore, PHT was associated with improved DFS, although the study was not powered to formally test this hypothesis (46). The TRYPHAENA and BERENICE trials evaluated dual HER2 blockade with HP and standard chemotherapy regimens with or without anthracyclines; they presented pCR rates of between 57 and 66% (51, 52). Different trials were also developed to evaluate dual blockade with HL plus chemotherapy in the neoadjuvant setting. In a recent meta-analysis including the GALGB 40601, Cher-LOB, NSABP-B41 and NeoALTTO trials, dual blockade was associated with an improvement in relapse-free survival (RFS) and OS, suggesting that the role of L should be reconsidered in EBC (53).

The functional assessment of treatment response in the neoadjuvant setting offers an opportunity to escalate therapy. Some trials evaluated the optimal treatment for patients who did not achieve pCR after neoadjuvant systemic therapy. In the KATHERINE trial, patients without pCR after neoadjuvant H and taxane-based chemotherapy were randomized to receive 14 cycles of T-DM1 or to complete one year of H. Treatment with T-DM1 was associated with improved three-year iDFS (54).

Other escalation strategies for higher-risk patients include the extension of adjuvant HER-directed therapies. As an example, the ExteNET trial, which randomized patients to receive one additional year of adjuvant neratinib or placebo after completing one year of H (55-57), showed an improved five-year iDFS in the neratinib arm. However, subgroup analysis found no benefit for HR-negative (HR-) patients and a statistically significant benefit in iDFS for HR-positive (HR+) patients. Treatment with neratinib was associated with diarrhea in 95% of patients and different strategies have been established to manage this side effect, improving the drug's tolerability (58).

Table 1 and Table 2 summarize the main trials in the neoadjuvant and adjuvant settings.

**Table 1.** Trials in the neoadjuvant setting.

Trial	Phase	Treatment	n	pCR	DFS	OS
TRAIN-2	III	A: FEC+H+P → Pac+CBDA+H+P	438	67 (60-73)	3y EFS: 92.7 (89.3-96.2)	3y: 97.7 (95.7- 99.7)
		B: Pac + CBDA		68 (61-74)	3y EFS: 93.6 (90.4-96.9)	3y: 98.2 (96.4- 100)
WSG-ADAPT	II	A: (H + P) B: (H + P) + Pac	134	34.4 (24.7-45.2) 90.5 (77.4-97.3)		
KRISTINE	III	A: T-DM1 + P	444	44	3y IDS: 93 (89.4-96.7)	3y: 97 (94.6- 99.4)
		B: TCH + P		56	3y IDS: 92 (86.7-97.3)	3y: 97.6 (95.5- 99.7)
TBCRC006	II	Lapatinib + H	64	27		
TBCRC023	II	A: Lapatinib + H	97	12		
		B: Lapatinib + H		28		
PER-ELISA	II	A: Letrozole + H + P	61	20.5 (11.1-34.5)		
		B: Pac + H + P		81 (57-93.4)		
SOLTI-PAMELA	II	Lapatinib + H	151	30 (23-39)		
NeoSphere	II	H + P	107	16.8 (10.3-25.3)	5y DFS: 80 (70-86)	
NeoSphere	II	A: TCHP	356	57.7 (47.4-69.4)		
		B: HP		35.4 (29.9-41.3)		
				29 (20.6-38.5)		
				45.8 (36.1-55.7)*	5y DFS	
		A: H + T		16.8 (10.3-25.3)†	81 (71-87)	
TRYPHAENA	II	B: P + H + T	417	24.0 (15.8-33.7)‡	86 (77-91)	
		C: P + H			73 (64-81)	
		D: P + T		*p=0.0141 vs A	73 (63-81)	
				†p=0.0198 vs A		
				‡p=0.003 vs B		
BERENICE	II	A: FEC+H+P → THP	225	56.2		
		B: FEC → THP		54.7		
		C: TCHP		63.6		
Meta-analysis (CALGB 40601, Cher-LOB, NSABP-B41, Neo- ALTTO)	II/III	A: ddAC → Pac+H+P	400	61.8 (54.7-68.6)		
		B: FEC → THP		60.7 (53.6-67.5)		
Cher-LOB	II	A: ChT + H	1410		RFS	OS
		B: ChT + H + Lapatinib			Pooled HR 0.62 (0.46-0.85)	Pooled HR 0.65 (0.43- 0.98)
		A: ChT + H			5y RFS: 77.8	
		B: ChT + Lapatinib		25 (13.1-36.9)	5y RFS: 77.1	
NSABP-B41	III	C: ChT + H + Lapatinib	121	26.3 (14.5-38.1)	5y RFS: 85.5	HR 1.00 (0.31- 3.27) (A vs C)
		ChT: Pac → FEC		46.7 (34.4-58.9)	HR 0.52 (0.23-1.15) (A vs C)	
		A: ChT + H			5y RFI: 84.3	5y: 94.5
NSABP-B41	III	B: ChT + Lapatinib	529	52.5 (44.9-59.5)	5y RFI: 78.6	5y: 89.4
		C: ChT + H + Lapatinib		53.2 (45.4-60.3)	5y RFI: 90	5y: 95.7
		ChT: AC → Pac		62 (54.3-68.8)	EFS: HR 0.66 (0.34- 1.25) (A vs C)	HR 1.00 (0.24- 1.67) (A vs C)

NeoALTTO	III	A: H + ChT B: Lapatinib + ChT C: H + Lapatinib + ChT	455	29.5 (22.4-37.5) 24.7 (18.1-32.3) 51.3 (43.1-59.5)	6y EFS: 67 6y EFS: 67 6y EFS: 74	6y: 82
						6y: 79 6y: 85
CALGB 40601	III	ChT: Pac A: H + ChT B: Lapatinib + ChT C: H + Lapatinib + ChT	305	46 (37-55) 32 (22-45) 56 (47-65)	EFS: HR 0.98 (0.64-1.91) (A vs C)	HR 0.85 (0.49-1.86) (A vs C)
						7y EFS: 79 7y EFS: 69 7y EFS: 93 7y: 88 7y: 84 7y: 96
ChT: Pac					EFS: HR 0.32 (0.14-0.71) (A vs C)	HR 0.34 (0.12-0.94) (A vs C)

T-DM1: trastuzumab-emtansine; ChT: chemotherapy; Pac: paclitaxel; H: trastuzumab; P: Pertuzumab; T: docetaxel; A: adriamycin; C: cyclophosphamide; CBDA: carboplatin; F: 5-fluorouracil; E: epirubicin; pCR: pathologic complete response; DFS: disease-free survival; OS: overall survival; EFS: ; RFI: ; RFS: ; IDS: y: year. pCR, DFS and OS are % (95% CI).

**Table 2.** Trials in the adjuvant setting.

Trial	Phase	Treatment	n	DFS	OS
HERA	III	A: 1y H B: 2y H C: Observation	3389	A: 2y DFS: 85.8 C: 2y DFS: 77.4 P<0.0001	A: 2y: 96 C: 2y: 95.1 p=0.26
				10y DFS: 69 10y DFS: 69 10y DFS: 63	12y: 79 12y: 80 12y: 73
BCIRG-006	III	A: AC → T B: AC → T → 1y H C: TC → 1y H	3222	HR 0.76 (0.68-0.86) (1 y vs obs)	HR 0.74 (0.64-0.86) (1 y vs obs)
				5y DFS: 75 5y DFS: 84 5y DFS: 81	5y: 87 5y: 92 5y: 91
NSABP B-31	III	A: AC → Pac B: AC → Pac + 1y H	3351	p<0.001 (A vs B) p=0.04 (A vs C)	p<0.001 (A vs B) p=0.04 (A vs C)
				10y DFS: 67.9 10y DFS: 74.6 10y DFS: 73	10y: 78.7 10y: 85.9 10y: 83.3
NCCTG N9831	III	A: AC → Pac B: AC → Pac + 1y H C: AC → Pac → 1y H		p<0.0001 (A vs B) p=0.0011 (A vs C)	p<0.0001 (A vs B) p=0.0075 (A vs C)
				10y DFS: 62.2 10y DFS: 73.7	10y OS: 75.2 10y OS: 85
Short-HER	III	A: AC or EC → T or Pac → 1y H B: T → FEC → 9w H	1254	p=<0.001 HR 0.6 (0.53-0.68)	p=0.001 HR 0.63 (0.54-0.73)
				5 year-DFS: 88.5 5 year-DFS: 85.5 HR 1.13 (90% CI, 0.89- 1.42) 8.7y DFS: HR 1.09 (90% CI, 0.88-1.35)	5y: 95.2 5y: 95 HR 1.07 (CI 90%, 0.74-1.56) 9y: 90 9y: 91 HR 1.18 (CI 90%, 0.86-1.62)
SOLD	III	A: T + 9w H → FEC B: T → FEC → 1y H	2174	5y DFS: 88 5y DFS: 90.5	5y: 94.7 5y: 95.9
				HR 1.39 (CI 90%, 1.12-1.72)	HR 1.36 (CI 90%, 0.98-1.89)
		A: 6m H	3384	7.5y DFS: 78.8	7.5y OS: HR 1.13 (0.92-1.39)

PHARE	III	B: 12m H		7.5y DFS: 79.6 p=0.39 HR 1.08 (0.93-1.25)	
PERSEPHONE	III	A: ChT + 6m H B: ChT + 1y H	4089	4y DFS: 89.4 4y DFS: 89.8 p=0.011 HR 1.07 (CI 90%,0.93-1.24)	4y: 93-8 4y: 94.8 HR 1.14 (CI 90%,0.95-1.37)
APT	II	Pac + H 12w → H 9m	406	7y DFS: 93.3 (90.4 - 96.2)	7y: 95 (92.4 - 97.7)
APHINITY	III	A: ChT + H 1y B: ChT + H + P 1y	4800	6y DFS: 88 6y DFS: 91 HR 0.76 (0.64-0.91)	6y: 94 6y: 95 p=0.17 <i>Immature data</i>
ALTTO	III	A: ChT + H → lapatinib B: ChT + H + lapatinib C: ChT + H	8381	6.9y DFS: 84 6.9y DFS: 85 6.9y DFS: 82 HR 0.86 (0.74-1.0) (B vs C) HR 0.93 (0.81-1.08) (A vs C)	6y: 92 6y: 93 6y: 91 HR 0.86 (0.7-1.06) (B vs C) HR 0.88 (0.71-1.08) (A vs C)
KAITLIN	III	A: AC → T-DM1 + P B: AC → P + H + P	1846	3y DFS: 93 3y DFS: 94 p=0.827 HR 0.98 (0.72- 1.32)	<i>Immature data for OS</i>
ExteNET	III	A: Neratinib 1y after H- based therapy B: Observation after H- based therapy	2840	5y DFS in HR+/≤ 1y post-H: A: 90.8 B: 85.7 HR 0.58 (0.41-0.82) 5y DFS in HR+/>1y post-H B: 89.4 HR 0.79 (0.55-1.13) 8y OS in HR+/>1y of prior H and residual disease after NA: B NA: benefit of 7.4% in group A vs B HR 0.60 (0.33-1.07)	8y OS in HR+/≤ 1y post-H: A: 91.5 B: 89.4 HR 0.79 (0.55-1.13) 8y OS in HR+/>1y of prior H and residual disease after NA: B NA: benefit of 9.1% in group A vs B HR 0.47 (0.23-0.92)
KATHERINE	III	A: T-DM1 x 14 cycles B: H x 14 cycles	1486	3y DFS: 88.3 3y DFS: 77 HR 0.5 (0.39-0.64)	<i>Immature data for OS</i>

T-DM1: trastuzumab-emtansine; T: docetaxel; Pac: paclitaxel; H: trastuzumab; P: pertuzumab; ChT: chemotherapy; pCR: pathologic complete response; DFS: disease-free survival; OS: overall survival; y: year; m: month; w: week; NA: neoadjuvant treatment; HR+: hormone receptor positive pCR, DFS and OS are % (95% CI).

## 2.2. HER2-positive advanced breast cancer – current approaches.

Although BC is frequently diagnosed in its early stages, approximately one-third of HER+ patients are metastatic at diagnosis or will develop distant relapse. The introduction of HER2-directed therapies, such as monoclonal antibodies, TKIs, ADCs and, more recently, immunomodulation strategies, has improved the prognosis of patients with advanced breast cancer (ABC).

Nowadays, the recommended first-line treatment for patients with HER2+ ABC with “*de novo*” or relapsed disease one year after completing adjuvant therapy is based on the CLEOPATRA phase III trial. Patients were randomized to receive HT plus P or placebo (59); after eight years of follow-up, there was an impressive increase in OS in the P arm. The ADC T-DM1 has been the standard second-line option in the last few years according to the results of the EMILIA trial (60), after demonstrating an improvement in both PFS

and OS in comparison with L plus capecitabine (61). The recently published DESTINY-Breast03 trial showed that treatment with T-DXd led to a highly significant 72% reduction in the risk of progression compared with T-DM1 in patients previously treated with HT (62). T-DXd is an ADC consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker (63). Treatment with TDXd was associated with interstitial lung disease and pneumonitis, but the incidence was lower than in previous trials with this drug. Drug-related interstitial lung disease was reported in 10.5% of patients receiving T-DXd; however, the number of grade 3 cases was low (2; 0.8%), and no grade 4/5 cases were reported. Nevertheless, careful monitoring is essential in its clinical use (64). Based on these data, T-DXd will replace T-DM1 as the standard second-line therapy. Different trials have evaluated new strategies after progression with two lines of HER2-targeted therapy, but none have included T-DXd as second-line therapy.

Tucatinib, an oral TKI very selective for HER2 protein, was compared with placebo in combination in both arms with H and capecitabine in the phase III trial HER2CLIMB. This trial included a heavily pretreated population, patients with HER2+ ABC who had progressed after H, P and T-DM1, and also included a significant proportion of patients with cerebral metastases. The HER2CLIMB results presented a significant improvement in PFS and OS (65, 66). Neratinib, an irreversible pan-HER TKI, was evaluated in patients previously treated with at least two lines of HER2 directed regimens, in combination with capecitabine compared with L plus capecitabine. The results showed a significant improvement in PFS but not in OS (23). The SOPHIA trial, another phase III trial that included patients with progression after at least two lines of anti-HER2 therapies, randomized patients to receive chemotherapy plus margetuximab versus chemotherapy plus H. Chemotherapy plus margetuximab showed a significant improvement in PFS but not OS (67). The ADC [vic]-trastuzumab duocarmazine was also compared with physician's treatment choice in patients with at least two prior lines of therapy or previous T-DM1 treatment. The results showed a significant improvement in PFS but not OS. Treatment with [vic]-trastuzumab duocarmazine was associated with 78.1% of eye toxicity, 21.2% of cases being grade  $\geq 3$  (68). Combination of L plus H showed an improvement in PFS and OS in comparison with L in heavily pretreated patients before the incorporation of P and T-DM1 into standard clinical practice (69).

Considering all these results, T-DM1 or tucatinib-based combinations seem to be the most interesting alternatives for HER2+ patients. Neratinib, margetuximab, L or H in combination with chemotherapy might be considered as later-line options.

### 2.3. HER2 heterogeneity as an opportunity to select the best therapy

HER2+ disease constitutes a biologically heterogeneous disease; thus, the appropriate dissection of its heterogeneity might afford a unique opportunity for therapy individualization and personalization.

Several meta-analyses regrouping neoadjuvant trials in HER2+ disease have demonstrated a strong association between HR- status and pCR, reporting better outcomes in HR- tumors (38, 70, 71). For many years, HER2+ disease has been considered a single tumor entity, but it is now known that not all clinically HER2+ tumors have the same genomic profile. As an example, all intrinsic molecular subtypes defined by PAM50 (72) can be identified in HER2+ tumors, with HER2-E being the most frequent (~47%), followed by Luminal B (~18–28%), Luminal A (11–23%) and Basal-like (7–14%). Furthermore, this distribution seems to be heavily influenced by HR status, with the HER2-E subtype representing 30% of the molecular subtypes within HR+ HER2+ BC and 75% within HR- HER2+ tumors (73, 74). Different trials, a systematic review and a meta-analysis have confirmed the association between the HER2-E intrinsic subtype and a higher pCR (70). In the adjuvant setting, the Short-HER study's molecular analysis showed that the HER2-E subtype was associated with worse metastasis-free survival in both therapy arms (75). However,

the biological heterogeneity of HER2+ tumors might also be related to the immune response after treatment induction of microenvironmental changes. The prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) has been evaluated in clinical trials involving HER2+ patients (23, 66-68, 76-78). The integration of both clinical and biological heterogeneity is an interesting concept for deciding HER2+ disease treatment. In this sense, tools such as HER2DX have been developed in EBC, which include tumor size, nodal status, stromal TILs, PAM50 subtypes and the expression of 13 genes (79). Using genomic and clinicopathological data from patients included in the Short-HER trial, this signature has been validated as a continuous variable in independent datasets from adjuvant and neoadjuvant trials. Interestingly, this signature has shown significant association with DFS and distant metastasis-free survival (DMFS), suggesting that treatment could be de-escalated in some HER2+ EBC patients.

The integration of molecular data for each patient might lead to therapy personalization and avoid unnecessary toxicities, as well as toward the development of more cost-effective treatments.


In the following two sections of the review, we address specific approaches to triple-positive tumors and the role of immunity and immunotherapy in HER2+ tumors.

### 3. The role of the estrogen receptor in HER2-positive tumors

HER2+ tumors are treated with anti-HER2 therapies combined with chemotherapy, regardless of estrogen receptor (ER) expression. Despite the obvious biological difference, HER2+/ER+ tumors are not, as yet, treated differently, and endocrine therapy is only added as maintenance after a standard anti-HER2 plus chemotherapy regimen. However, in the last years, effort has been focused on finding combinations to improve chemotherapy regimen toxicity. One example is the PHERgain phase II trial, in which 67% of the patients were ER+. A trastuzumab plus pertuzumab chemotherapy-free regimen was evaluated, and hormone therapy was added in ER+ patients. Although the chemotherapy-free regimen had a significantly lower pCR rate after the neoadjuvant regimen, 35.4% of the patients achieved a pCR after neoadjuvant treatment. Interestingly, with the addition of endocrine therapy, ER+ status was not a predictor of treatment response. However, the HER2 immunochemistry score had an impact on pCR: a HER2 3+ immunohistochemistry score achieved a higher pCR rate than tumors with a 2+ score (80). Another example is the PERTAIN phase II trial, that combined an aromatase inhibitor (AI) (anastrozole or letrozole) plus trastuzumab, with or without pertuzumab in HER2+/ER+ metastatic BC patients with no prior systemic therapy. The AI plus trastuzumab and pertuzumab group had a significant increase in mPFS, 18.89 vs 15.80 months (hazard ratio, 0.65; 95% CI, 0.48 to 0.89;  $p=0.007$ ) (81). Understanding the biological crosslink between the HER2 and ER pathways will help improve treatment and, therefore, patient outcomes in the future.

#### 3.1. Crosslink between HER2 and estrogen receptors

The evolution, prognosis and treatment response of HER2+ BC disease differ depending on ER status due to the diverse biological characteristics. It has been well described that the ER and HER pathways are frequently deregulated in BC (82). When ER is not expressed, the HER2 pathway is associated with a more proliferative BC and an immune activation stroma with elevated TILs. Deregulation can occur by upstream signaling molecule alteration or due to a genetic/epigenetic change in downstream signaling molecules. ER acts as a hormone nuclear transcription factor and binds specific DNA sequences to promote the proliferation and survival of genes (83). Furthermore, ER is involved in non-nuclear pathways and can interact at a cytoplasmic level with several tyrosine kinase receptors (e.g., HER2) and downstream signaling factors (84). These two ER pathways interact at several levels with many cellular kinase networks to undergo bidirectional cross-talk that increases the ER signaling and kinase-related pathways (85). Additionally, ER can interact with HER signaling members via G protein interaction (84) (Figure 1).



**Figure 1.** Interaction between ER and HER2 pathways. In ER+/HER2+ tumors, the hyperactivation of HER2 signaling activates downstream kinases and downregulates ER expression, not only at the protein level but also mRNA expression. (Adapted from “HER2 Signaling Pathway”, by BioRender.com (2022). Retrieved from <https://app.biorender.com/biorender-templates>).

An *in vitro* study using BC cell lines described significantly lower ER levels when the HER2 gene was transfected, presenting an inverse correlation between the levels of HER2 overexpression and ER (86). Moreover, it has been suggested that the HER signaling factor could reduce both mRNA and protein levels of ER expression. BC subtypes based on the PAM50 classification within HER2 tumors differ according to their ER status. Interestingly, more than two out of three HER2+/ER+ tumors are luminal A or B, when analyzed via the PAM50 signature. These are ER-dependent tumors with low activation of the HER2/EGFR-pathway (87); this subtype benefits less from anti-HER2 treatments (88). The survival prognosis and time to relapse after radical treatment differs between HER2/ER+ and HER2+/ER-. For example, overall survival five years after EBC diagnosis was significantly higher in HER2+/ER+ (88.2%) compared with the HER2+/ER- subgroup (83.9%)(89). After five years, the recurrence risk in the HER2+/ER- group decreased progressively, however it was conserved over time in the HER2/ER+ group (7). Based on these findings, in the future, ER+/HER2+ BC might be defined as a distinct molecular disease (90).

### 3.2. Efficacy of anti-HER2 and endocrine therapy in ER+/HER2+

Due to the relationship and ample crosstalk between the ER and HER2 signaling pathways, therapeutic strategies blocking only one pathway result in the upregulation of the other, leading to treatment resistance (91, 92). HER2 overexpression has been related to *de novo* and acquired resistance to endocrine therapies (92). Multiple trials have demonstrated the lower pCR rates in HER2+/ER+ compared with HER2+/ER- patients using chemotherapy and dual anti-HER2 target therapy in the neoadjuvant setting (9, 93, 94).

A possible strategy to improve treatment performance in HER2+/ER+ would be to prolong anti-HER2 treatment. As an example, the TBCRC023 phase II trial, in which 65%

of patients were HER2+/ER+, reported that increasing the length of anti-HER2 treatment (trastuzumab/lapatinib) from 12 to 24 weeks increased the pCR rate (9% vs. 33%) in HER2+/ER+ patients who also received Letrozole. Surprisingly, this benefit was not seen in HER2+/ER- patients (95). In the same direction, the ExteNET trial showed that adding sequential anti-HER2 treatment with trastuzumab and Neratinib for two years was beneficial in HER2+/ER+ but not in HER2+/ER- patients (96). An explanation of this fact could be that the continued blocking of both HER2 and ER pathways would induce a decrease in proliferation and apoptosis. In this sense, an *in vitro* study demonstrated that continuous dual inhibition of the HER2 pathway with Trastuzumab plus Lapatinib led to ER function as a critical escape/survival pathway in HER2+/ER+ cells, thus, a complete blockade of HER2 together with the ER pathway may be required for these patients (97).

Multiple efforts have been made to improve response rates, time to relapses and survival, including improved cancer patient selection. For example, when ESR1 and ERBB2 expression were quantified in the NeoALTTO trial, high levels of ERBB2/HER2 and low levels of ESR1 were associated with higher pCR rates in all treatment arms (98). Also, in the adjuvant setting, NSABP-31 trial analysis succeeded in clustering patients into three groups using an eight-gene signature regarding ESR1 and ERBB2 expression. As expected, the low-intermediate ESR1 and high ERBB2 group received the most significant benefit from adjuvant treatment using anti-HER2 therapies (99). Regarding intrinsic subtypes based on PAM50, many studies demonstrated that an HER-2 enriched (HER2-E) subtype predicts pCR after HER2 neoadjuvant treatment (100). Surprisingly, ER status by immunochemistry loses the association with pCR when the PAM50 subtype is considered; Therefore, intrinsic subtypes may better reflect sensitivity to treatment than BC cell biology. In HER2+ and HER2-E tumor cell lines, treatment with anti-HER2 drugs induces a low-proliferative luminal phenotype. Interestingly, suspension of HER2 therapy *in vitro* reverts them to the original HER2-E phenotype, suggesting that HER2-targeted therapy should not be stopped despite resistance. These changes were more evident in ER+ disease, probably due to ER and HER2 signaling crosslinking (101). Another signature used in HER2+/ER+ tumors is Rbsig, which analyzes 87 genes to build a signature related to RB1 loss-of-function. Higher Rbsig scores were found to correlate with a higher response to chemotherapy whereas low Rbsig expression identified HER2+/ER+ patients with low pCR rates. These findings suggest that patients with a low Rbsig may be potential candidates for a de-escalated regimen with HER2-targeted therapy plus hormonal therapy and CDK 4/6 inhibitors (102). Finally, high Rbsig HER2+/ER+ tumors have a lower tumor-infiltrating lymphocyte (TIL) rate than high Rbsig HER2+/ER-. However, a higher TIL rate is associated with increased pCR rates after neoadjuvant treatment in both HER2+/ER+ and HER2+/ER- tumors (103). In summary, a broad HER2 pathway blockade is needed in HER2+, which, together with ER inhibition, would be the optimal therapy.

### 3.3. Future Combination/ongoing studies to improve the efficacy of endocrine anti-HER2 in ER+/HER2+

Understanding the molecular biology and resistance mechanisms in HER2 and ER BC is necessary for the optimization of future drug combinations in HER2+/ER+ disease. For example, one-third of HER2-/ER+ metastatic patients carry a PI3KCA mutation (104, 105). The role of hyperactivation of the downstream PI3K-AKT pathway has been broadly studied and associated with resistance to HER2-targeted therapy in preclinical models, especially trastuzumab (106, 107). PI3K-AKT pathway activation might be induced by PTEN loss-of-function or a PI3KCA mutation, which are more frequent in HER2+/ER+ patients than in HER2+/ER- (87). After progression to anti-HER2 treatment, some trials have attempted to block PI3K-AKT using mTOR or PI3K inhibitors in combination with anti-HER2 treatment. Alpelisib plus TDM-1 in heavily pretreated HER2+ patients have shown promising results with an overall response rate of 43% (108). Nevertheless, the combination of PI3K inhibitors with anti-HER2 drugs seems to induce severe side effects and most trials are still in the early phases, aiming to establish the maxim tolerated dose

(109-112). Other strategies to reverse trastuzumab resistance via hyperactivation of the PIK/AKT/mTOR pathway have been attempted. One example is the BOLERO-1 phase III trial that evaluated the efficacy of adding an mTOR inhibitor, such as everolimus, to trastuzumab plus paclitaxel in the first-line treatment of HER2+ tumors. There was no significant difference in PFS between the two groups in the overall population. However, in the HR- group, there was a 7.2-month increase in PFS with everolimus (113).

Over the last five years, there have been breakthroughs in ER+ BC disease: Three different CDK 4/6 inhibitor drugs have been approved: Abemaciclib, Palbociclib and Ribociclib. They have all demonstrated increased PFS when combined with hormonotherapy in HER2-/ER+ (114-116). Furthermore, Ribociclib, in combination with letrozole, achieved a 12-month increase in OS, reaching a median OS of 53.7 months for the ribociclib in the combination arm vs 41.5 months in the letrozole plus placebo arm (HR, 0.73; 95% CI 0.59-0.90)(117). Although CDK 4/6 suppresses Rb phosphorylation and blocks the cell cycle in the G1 phase, other mechanisms of action have been suggested. First, selective CDK4/6 inhibitors promote anti-tumor immunity by increasing type III interferon production and enhancing tumor antigen presentation. Indirect DNA methyltransferase-1 inhibition from CDK 4/6 inhibition also increases T cell cytotoxic activity and decreases immunosuppressive T reg cell (118). Secondly, it also reduces TSC2 phosphorylation and attenuates mTORC1 activity, which could sensitize tumors to blocked EGFR/HER2. In PDX models, CDK4/6 inhibitors help sensitize HER-2+ breast tumors to HER2-targeted therapies (119); however, there are no reliable biomarkers to predict the benefit of CDK 4/6 inhibition. The Basal intrinsic subtype based on PAM50 may be the only one showing no improvement with CDK 4/6 inhibitors in HER2-/ER+ patients. In a retrospective analysis of MONALEESA 2, 3 and 7 with 1,160 tumors, the basal-like subtype subgroup (n=30) was the only one that did not benefit from the addition of Ribociclib (HR 1.15, p=0.77) (120).

On the other hand, some HER2+/ER+ patients might benefit from dual pathway inhibition with the combination of HER2-targeted therapy plus CDK 4/6 inhibitors plus hormonotherapy. Some trials have already tested this triple combination in HER2+/ER+ patients. In the MonarchHER phase II trial, the triple combination of CDK inhibitor + hormonotherapy + antiHER2 (abemaciclib + fulvestrant + trastuzumab) increased PFS with respect to other combinations. At the moment, some ongoing phase III trials, like PATINA, will help us understand which patients could benefit more from the triple combination and thus improve treatment personalization (Table 3).

**Table 3.** Trials testing CDK4/6 inhibitors.

Trial	Phase	Treatment	n	Primary endpoint	Results
PATRICIA	II	Palbociclib 200 mg 2w on 1w off or 125 3w on 1w off + H	71 (56 ER+)	PFS at 6 months	6m PFS in ER+ patients treated with Palbociclib + H 42.8% vs 46.4%
		600 mg sc every 3w			Luminal disease by PAM50 had longer PFS (10.6m vs 4.2m)
		ER+ patients were treated with Letrozole vs Placebo			
Ribociclib, NCT02657343	Ib/II	Ribociclib 400 mg daily (phase II) + H iv	13 (ER+ in 8)	MTD and CBR	1 experienced stable disease >24w PFS was 1.3m
Ribociclib, NCT02657343	Ib	Ribociclib 400 mg given on days 8-21 of a 21-day cycle with T-DM1	12	MTD for phase II	PFS was 10.4m
MonarchHER	II	A: Abemaciclib 150 mg/12h + H iv B: Abemaciclib + BPC ChT C: Abemaciclib + fulvestrant im + H iv	237 physician's choice (all HER+/ER+)	PFS between groups 8.3m vs 5.7m and 5.7m compared with the other groups	Abemaciclib + H + Fulvestrant longer PFS: 8.3m vs 5.7m and 5.7m compared with the other groups
PATINA	III	H+P with endocrine therapy (letrozole, anastrozole, exemestane or fulvestrant) +/- palbociclib	496 already recruited	PFS	Not reported yet
ASPIRE	I/II	Palbociclib (100 and 125 mg 3w on 1w off) + H iv + P iv + Anastrozole	36 planned	DLT, MTD, CBR	Not reported yet

MTD: Maximum Tolerated Dose; PFS: Progression-Free survival; CBR: Clinical Benefit Rate; BPC: Best Practice Choice; ROR: Rate of Overall Response; DLT: Dose Limiting Toxicity; iv: intravenous; im: intramuscular; sc: subcutaneous; H: trastuzumab; P: pertuzumab; ChT: chemotherapy; m: months; w: weeks.

#### 4. Tumor immunity and immunotherapy in HER2-positive breast cancer

##### 4.1. Role of tumor immunity in HER2-positive breast cancer

The role of immunotherapeutic agents in HER2+ BC is becoming increasingly relevant as this BC subgroup has higher stromal TIL levels, implying that HER2+ disease is usually more immunogenic compared with other BC tumors (121-123). Thus, several immunotherapeutic agents, such as novel HER2-directed mAbs, ADCs, vaccines and adoptive T cell therapies are currently being explored in patients with HER2+ tumors. However, not all HER2+ tumors are equally immunogenic and specific BC molecular subgroups beyond immunohistochemical (IHC) subtypes show differential response. Some subgroups (e.g., HER2-E) are more immunogenic than others (e.g., Luminal A/B)(124). Both the percentage of TILs and the expression of different immune cells in the tumor microenvironment (CD8+, CD4+ Th1 and NK cells) have been associated with better prognosis; they may also contribute to the therapeutic effects of anti-HER2 targeted therapy (125).

In HER2+ BC, the interplay between the immune system and the tumor is complex and dynamic, involving the interaction of different HER2-targeted treatments and additional treatments such as chemotherapy, hormonotherapy and the modulating action of HR status and tumor biology (122). In addition, the different anti-HER2 treatments seem to modulate tumor microenvironment and *vice versa*, and the presence of high tumor immunity has been linked to a differential effect of these therapies (126, 127). For example,

in animal models, lapatinib promotes tumor infiltration by CD4 + CD8 + IFN- $\gamma$ -producing T cells via a STAT1-dependent pathway. STAT1 deficiency reduces the therapeutic activity of lapatinib, suggesting that immune activation can play a role in its antitumor activity (128). Another example, from the Neo ALTTO trial, is that T cell-driven immune signatures have been associated with pCR in patients treated with lapatinib, which highlights the role of immunity in modulating the activity of HER2-targeted therapy (128, 129). The expression of PD1 in the tumor microenvironment is a mechanism of tumor evasion, the combination of anti-HER2 monoclonal antibodies with anti-PD1 is synergic, improving therapeutic activity, reason why these combinations are being tested in different trials (130).

Furthermore, the modulation of immune cells occurring in HER2+ BC has shown a clinical impact on treatment efficacy (131, 132). In HER2+ BC, the NeoSphere (133) and NeoALTTO(134) trials have shown that tumors with low baseline TILs had lower pCR-rates. Additionally, both NeoALTTO (134) and TRYPHAENA (135) trials found that TILs were associated with improved event-free survival when systemic therapy was given in the neoadjuvant setting. Loi *et al.*, reported that TILs were predictive of benefit to adjuvant trastuzumab in the FinHER study (136). A pooled analysis of six prospective neoadjuvant clinical trials found that increased TIL levels were associated with higher pCR rates and improved DFS in HER2+ BC (137); however, the analysis did not show an association between increased TIL levels and OS. In contrast, data from the adjuvant N9831 trial suggested that the presence of high TIL levels was associated with an improvement in recurrence-free survival in patients who received chemotherapy alone, but not in patients treated with chemotherapy plus trastuzumab (138). Thus, higher levels of TILs have been associated with better outcome and response to anti-HER2 treatment; however, an enhanced understanding of the role played by the immune system in modulating therapy response to different anti-HER2 agents is needed.

Due to the promising role of immunotherapy in HER2+ BC, the recent introduction of immune checkpoint inhibitors and other immunotherapeutic agents capable of unleashing an anti-tumoral immune response opens new possibilities for therapeutic combinations in this setting.

#### *4.2. Trials testing combinations with immune-therapeutic drugs in HER2-positive breast cancer.*

The most important trials testing immunotherapeutic agents in HER2+ disease are reported in Table 4.

Table 4. Trials testing immunotherapeutic agents in HER2+ disease.

NCI identifier	Phase	Recruitment	Setting	Subtype	Immunotherapies	Combined treatments	Treatment
NCT03241173	I/II	Active, not recruiting	Metastatic or LA	All	Ipilimumab and/or nivolumab	INCAGN01949	Anti-CTLA4
NCT03126110	I/II	Active, not recruiting	Metastatic or LA	All	Ipilimumab and/or nivolumab	INCAGN01876	Anti-CTLA5
NCT03328026	I/II	Recruiting	Metastatic or LA	All	Ipilimumab or pembrolizumab	SV-BR-1-GM, cyclophosphamide, and interferon inoculation	Anti-CTLA6
NCT02129556	I/II	Active, not recruiting	Metastatic	HER2+ resistant to H	Pembrolizumab	H	anti-PDL1; anti-PD1
NCT01772004	I	Active, not recruiting	Metastatic	HER2+	Avelumab	H	Anti-PD1
NCT03747120	II	Recruiting	Neoadjuvant	HER2+	Pembrolizumab	Neoadjuvant H + P + Pac	Anti-PDL1
NCT03523572	I	Recruiting	Advanced	HER2+	Nivolumab	Trastuzumab deruxtecan	Anti-PDL1; Anti-PD3
NCT02649686	I	Active, not recruiting	Metastatic	HER2+	Durvalumab	H	Anti-PDL1; Anti-PD4
NCT02924883	II	Active, not recruiting	Metastatic	HER2+	Atezolizumab	T-DM1	Anti-PDL1; Anti-PD5
NCT03125928	II	Recruiting	Metastatic	HER2+	Atezolizumab	Pac + H + P	Anti-PDL1; Anti-PD6
NCT03620201	I	Recruiting	Stage II-III	HER2+	M7824 (anti-PD-L1 fusion protein)		Anti-PDL1; Anti-PD7
NCT05180006	I	Recruiting	Neoadjuvant	HER2+ TNBC	Atezolizumab	H + P	Anti-PDL1
NCT02336984	I/II	Active, not recruiting	DCIS	HER2+	HER2-pulsed DC1	H + P	Vaccine
NCT02061423	I	Active, not recruiting	Stage I-III	HER2+	HER2-pulsed DC vaccine		Vaccine
NCT03384914	II	Recruiting	Stage I-III	HER2+	DC1 vaccine		Vaccine
NCT03387553	I	Active, not recruiting	Stage II/III	HER2+	DC1 vaccine		Vaccine
NCT03113019	I	Active, not recruiting	Stage II-IV	HER2+ T NBC	DC-based vaccine		Vaccine
NCT03113019	I	Active, not recruiting	Stage II-IV	HER2+ T NBC	DC-based vaccine		Vaccine
NCT03630809	II	Not yet recruiting	DCIS or inflammatory	HER2+	HER2-pulsed DC1		Vaccine
NCT01376505	I	Recruiting	Metastatic	HER2 1+, 2+, or 3+ by IHC	MVF-HER-2 (597-626)-MVF- HER-2 (266-296) peptide vaccine		Vaccine
NCT03632941	II	Recruiting	Metastatic	HER+	VRP-HER2 immunizations plus pembrolizumab.		Vaccine

T-DM1: trastuzumab-emtansine; Pac: paclitaxel; H: trastuzumab; P: pertuzumab; LA: locally advanced; DC: dendritic cells; IHC: immunohistochemistry; DCIS: ductal carcinoma in situ; TNBC: triple-negative breast cancer.

Immune-therapeutic agents have mainly been tested and approved for triple-negative BC patients. Their use in other BC subgroups, such as luminal B BC or pretreated HER2+ BC, has also been explored but results are still controversial (13, 14, 139, 140). Several preclinical and clinical studies have explored the potential for immunotherapy to improve clinical outcomes in HER2+ disease.

There are few reports published on the use of CTLA-4 inhibitors in BC; Ipilimumab was evaluated, with or without cryoablation, in early-stage BC patients. Nineteen patients were included in this study, of whom two had HER2+ disease (130). They detected a favorable increase in the proportion of activated effector T cells among patients receiving ipilimumab treatment alone or with cryoablation. The combination treatment also showed a modest increase in the ratio of intratumoral T effector cells relative to Tregs (139).

Controversial results were reported for anti-PDL1 treatment in HER2+ BC (13, 140). PANACEA, a single-arm, multicenter, phase Ib-2 trial. Pembrolizumab plus trastuzumab was tested in PD-L1-positive advanced HER2+ BC tumors using a 3 + 3 dose-escalation of intravenous pembrolizumab (2 mg/kg and 10 mg/kg, every three weeks) plus 6 mg/kg intravenous trastuzumab. It was shown to be safe with activity and durable clinical benefit in PD-L1-positive, trastuzumab-resistant, advanced, HER2+ BC patients (13).

KATE2, a randomized, double-blind, placebo-controlled, phase II study, included 330 patients, of whom 202 were randomly allocated either atezolizumab (n=133) or placebo (n=69), plus T-DM1 in HER2+ ABC previously treated with trastuzumab and a taxane. The addition of atezolizumab to T-DM1 did not induce a clinically significant improvement in PFS and was associated with more adverse events (14).

In the JAVELIN Solid Tumor trial, avelumab was tested in 168 patients with metastatic BC, in which 26 patients (15.5%) had HER2+ BC. Unfortunately, no benefit in terms of overall response rate was seen in HER+ patients.

Based on these results, further studies in this BC subtype should focus on a PD-L1-positive population and be carried out in less heavily pretreated patients (141). Another phase I trial, with 15 patients with HER2+ progressive metastatic BC treated with trastuzumab combined with durvalumab, found that none of these patients achieved a partial response. Four of the patients had stable disease; however, none had tumors harboring PD-L1 expression (142).

Further studies testing other immune-checkpoint inhibitors in combination with chemotherapy and anti-HER2 treatments are being explored to better characterize the efficacy of immune-checkpoint inhibitors in this setting (Table 4).

Beyond immune checkpoint inhibitors, HER2 is a remarkable therapeutic target for peptide-based cancer vaccines. HER2 drives oncogenic potential and its expression on the surface of HER2-overexpressing breast carcinomas can be remarkably higher than on normal cells. Therapeutic cancer vaccines are intended to treat existing tumors by enhancing the anti-tumor immune response. The use of dendritic cells (DCs) as a vaccine strategy has the advantage of presenting vaccine antigens to other immune system cell types. HER2 vaccination is currently under development using several different clinical development strategies. Preclinical studies have demonstrated the potential for generating HER2-loaded DCs as well as DCs engineered to express HER2 antigen epitopes (143, 144).

Finally, the design and development of different HER2-directed ADCs explained above (section 2) are also key immune-related strategies, which produce increased cytotoxicity with a reduction in chemotherapy off-target adverse effects due to the antibody-driven drug internalization.

This review provides rationale for investigating and optimizing the use of immunotherapeutic agents such as immune checkpoint inhibitors, therapeutic vaccines and adoptive T cell immunotherapy in HER2+ BC.

## 5. Conclusions

The current clinical development of anti-HER2 treatments has fortunately changed the paradigm of HER2+ BC; however, up to 25% of HER2+ BC patients will relapse during the course of the disease. In the last decade, several strategies for more personalized medicine, including both escalated and de-escalated strategies have been explored. Beyond anti-HER2 targeted therapy, other approaches including combinations with endocrine therapy plus anti-CDK4/6 inhibitors or immune-therapeutic agents have also been investigated with promising results. Only a greater level of understanding of the underlying molecular biology and the rationale for the different strategies available will shed light on the subgroup of patients that are still at risk of relapse.

**Author Contributions:** Original idea and planning: AF and EF. Writing—All authors. Reviewing and editing—All authors. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding. EF is supported by a Rio Hortega grant from the Instituto de Salud Carlos III (ISCIII- CM20/00027).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We would like to thank the Catalan Institute of Oncology for their support.

**Conflicts of Interest:** AFD declares travel expenses from Roche, MSD and Novartis. EF declares a consulting and advisory role for Novartis; research funding from Pfizer and travel expenses from Lilly, Novartis and Pfizer. AP declares travel expenses from Roche and BMS. MM has participated as an advisor of Lilly, Seagen, Novartis, Pfizer, Roche, and Kern; her institution has received research funding from Pfizer, Roche, Eisai, AstraZeneca and Kern and travel expenses from Gilead. MB declare no potential conflict of interest.

## References

1. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. *Cancer Invest.* 2010;28(9):963-8.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science.* 1987;235(4785):177-82.
3. Pernas S, Barroso-Sousa R, Tolaney SM. Optimal treatment of early stage HER2-positive breast cancer. *Cancer.* 2018;124(23):4455-66.
4. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. *Cochrane Database Syst Rev.* 2012;2012(4):Cd006243.
5. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Jr., et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol.* 2014;32(33):3744-52.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001;344(11):783-92.
7. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet.* 2017;389(10075):1195-205.
8. Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martín M, Jasiówka M, et al. Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (Ad'T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (Ad'TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. *Cancer Research.* 2016;76.
9. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. *J Clin Oncol.* 2016;34(6):542-9.
10. André F, Shahidi J, Lee C, Wang K, Krop I. 197TiP - Phase III study of [fam-] trastuzumab deruxtecan vs investigator's choice in T-DM1-pretreated HER2+ breast cancer. *Annals of Oncology.* 2019;30:iii63.
11. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *New England Journal of Medicine.* 2020;382(7):597-609.

12. Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, et al. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. *Clin Cancer Res.* 2020;26(22):5820-9.
13. Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncol.* 2019;20(3):371-82.
14. Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. *Lancet Oncol.* 2020;21(10):1283-95.
15. Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, et al. Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). *Cancer Research.* 2019;79(4\_Supplement):OT3-02-7-OT3-7.
16. Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. *npj Breast Cancer.* 2020;6(1):10.
17. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. *New England Journal of Medicine.* 2015;372(8):724-34.
18. Bakhtiar R. Antibody drug conjugates. *Biotechnology Letters.* 2016;38(10):1655-64.
19. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. *Cancer Research.* 2008;68(22):9280-90.
20. Xia W, Mullin RJ, Keith BR, Liu L-H, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. *Oncogene.* 2002;21(41):6255-63.
21. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase. *Cancer Research.* 2004;64(11):3958-65.
22. Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. *Molecular Cancer Therapeutics.* 2020;19(4):976-87.
23. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with  $\geq 2$  HER2-directed regimens: Phase III NALA trial. *Journal of Clinical Oncology.* 2020;38(27):3138-49.
24. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. *Clinical Cancer Research.* 2009;15(24):7479-91.
25. Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, et al. Towards personalized treatment for early stage HER2-positive breast cancer. *Nature Reviews Clinical Oncology.* 2020;17(4):233-50.
26. Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. *npj Breast Cancer.* 2021;7(1):56.
27. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2014;32(33):3744-52.
28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *The New England journal of medicine.* 2005;353(16):1659-72.
29. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *The New England journal of medicine.* 2011;365(14):1273-83.
30. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. *The Cochrane database of systematic reviews.* 2012;2012(4).
31. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *The Lancet.* 2017;389(10075):1195-205.
32. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. *Annals of oncology : official journal of the European Society for Medical Oncology.* 2018;29(12):2328-33.
33. Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvilinen P, Utriainen M, et al. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. *JAMA oncology.* 2018;4(9):1199-206.
34. P.F. Conte AF, Bisagni, A.A. Brandes, M. Donadio, O. Garrone, F. Piacentini, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Musolino, A. Ferro, S. Danese, C. Zamagni, O. Nanni, M.V. Dieci, R. Vicini, S. Balduzzi, V. Guarneri. Nine weeks vs 1 year adjuvant trastuzumab: long term outcomes of the ShortHER randomised trial. *J OncologyPRO. Annals of Oncology* 2021:S37-S47.
35. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. *The Lancet Oncology.* 2013;14(8):741-8.
36. Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet (London, England).* 2019;393(10191):2599-612.

37. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *The New England journal of medicine*. 2015;372(2):134–41.

38. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet (London, England)*. 2014;384(9938):164–72.

39. van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology*. 2018;19(12):1630–40.

40. van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. *JAMA Oncol*. 2021;7(7):978–84.

41. Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2017;28(11):2768–72.

42. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *The Lancet Oncology*. 2018;19(1):115–26.

43. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2019;37(25):2206–16.

44. Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, et al. TBCRC023: A randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer. *Clinical Cancer Research*. 2020;26(4):821–7.

45. Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, et al. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. *Journal of the National Cancer Institute*. 2020;112(1):46–54.

46. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *The Lancet Oncology*. 2016;17(6):791–800.

47. Pérez-García JM, Gebhart G, Borrego MR, Stradella A, Bermejo B, Schmid P, et al. Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. *The Lancet Oncology*. 2021;22(6):858–71.

48. Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer M, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. *Journal of Clinical Oncology*. 2021;39(13):1448–57.

49. Piccart-Gebhart M, Holmes E, Baselga J. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2016;34(10):1034–42.

50. Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2022;40(5):438–48.

51. Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): A phase II, open-label, multicenter, multinational cardiac safety study. *Annals of Oncology*. 2018;29(3):646–53.

52. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Annals of oncology : official journal of the European Society for Medical Oncology*. 2013;24(9):2278–84.

53. Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. *ESMO open*. 2022;7(2):100433.

54. von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *The New England journal of medicine*. 2019;380(7):617–28.

55. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2017;18(12):1688–700.

56. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2016;17(3).

57. Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. *Clinical breast cancer*. 2021;21(1):80–91.e7.

58. Barcenas CH, Hurvitz SA, Palma JAD, Bose R, Chan A, Chien AJ, et al. Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. [https://doi.org/10.1200/JCO.2019.3715\\_suppl548](https://doi.org/10.1200/JCO.2019.3715_suppl548). 2019;37(15\_suppl):548--.

59. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. *The Lancet Oncology*. 2020;21(4):519--30.

60. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *The New England journal of medicine*. 2012;367(19):1783--91.

61. Geyer CE, Forster J, Lindquist D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *Advances in Breast Cancer*. 2008;5(2):45.

62. Cortes J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <https://doi.org/10.1056/NEJMoa2115022>. 2022;386(12):1143--54.

63. Ogitani Y, Aida T, Hagiwara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. *Clinical Cancer Research*. 2016;22(20):5097--108.

64. Kumagai K, Aida T, Tsuchiya Y, Kishino Y, Kai K, Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. *Cancer science*. 2020;111(12):4636--45.

65. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *The New England journal of medicine*. 2020;382(7):597--609.

66. Curigliano G, Mueller V, Borges VF, Hamilton EP, Hurvitz SA, Loi S, et al. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). [https://doi.org/10.1200/JCO.20213915\\_suppl1043](https://doi.org/10.1200/JCO.20213915_suppl1043). 2021;39(15\_suppl):1043--.

67. Rugo HS, Im SA, Cardoso F, Corts J, Curigliano G, Musolino A, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*. 2021;7(4):573--84.

68. Manich CS, O'Shaughnessy J, Aftimos PG, van den Tweel E, Oesterholt M, Escriv de R. LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing vic-trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. *Annals of Oncology*. 2021;32:S1288.

69. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(21):2585--92.

70. Schettini F, Pascual T, Conte B, Chic N, Bras-Maristany F, Galvn P, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. *Cancer Treatment Reviews*. 2020;84.

71. Gunter von Minckwitz MU, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *Journal of Clinical Oncology*. 2012;30(15):1796--804.

72. Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. *BMC medical genomics*. 2015;8(1).

73. Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. *Breast (Edinburgh, Scotland)*. 2021;59:339--50.

74. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2014;20(2):511--21.

75. Conte PF, Griguolo G, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, et al. PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial. [https://doi.org/10.1200/JCO.2019.3715\\_suppl544](https://doi.org/10.1200/JCO.2019.3715_suppl544). 2019;37(15\_suppl):544--.

76. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura Ca. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. *JAMA oncology*. 2015;1(4):448--55.

77. Dieci M, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2016;27(10):1867--73.

78. Denkert C, von Minckwitz G, Bräse J, Sinn B, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *Journal of Clinical Oncology*. 2015;33(9):983--91.

79. Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci M, et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *The Lancet Oncology*. 2020;21(11):1455--64.

80. Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, et al. Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. *Lancet Oncol.* 2021;22(6):858-71.

81. Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, et al. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. *J Clin Oncol.* 2018;36(28):2826-35.

82. Giuliano M, Trivedi MV, Schiff R. Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. *Breast Care (Basel).* 2013;8(4):256-62.

83. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. *Clin Cancer Res.* 2001;7(12 Suppl):4338s-42s; discussion 411s-412s.

84. Nemere I, Pietras RJ, Blackmore PF. Membrane receptors for steroid hormones: signal transduction and physiological significance. *J Cell Biochem.* 2003;88(3):438-45.

85. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. *Endocr Rev.* 2008;29(2):217-33.

86. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst.* 2003;95(2):142-53.

87. Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. *Nat Commun.* 2016;7:12222.

88. Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. *Ann Oncol.* 2016;27(8):1519-25.

89. Hwang KT, Kim J, Jung J, Chang JH, Chai YJ, Oh SW, et al. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database. *Clin Cancer Res.* 2019;25(6):1970-9.

90. Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M. What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer? *Clin Cancer Res.* 2020;26(12):2783-8.

91. Flägeng MH, Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, et al. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. *Br J Cancer.* 2009;101(8):1253-60.

92. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. *Cancer Res.* 2006;66(16):8266-73.

93. Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, et al. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. *Breast Cancer Res.* 2017;19(1):16.

94. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 2018;19(1):115-26.

95. Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, et al. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. *Clin Cancer Res.* 2020;26(4):821-7.

96. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017;18(12):1688-700.

97. Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. *Breast Cancer Res.* 2011;13(6):R121.

98. Fumagalli D, Venet D, Ignatiadis M, Azim HA, Jr., Maetens M, Rothé F, et al. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncol.* 2017;3(2):227-34.

99. Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, et al. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. *J Natl Cancer Inst.* 2013;105(23):1782-8.

100. Shen G, Zhao F, Huo X, Ren D, Du F, Zheng F, et al. Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. *Front Oncol.* 2021;11:632357.

101. Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, et al. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. *Nature Communications.* 2020;11(1).

102. Risi E, Grilli A, Migliaccio I, Biagioli C, McCartney A, Guarducci C, et al. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. *Breast Cancer Res Treat.* 2018;170(2):329-41.

103. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol.* 2018;19(1):40-50.

104. Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. *Breast Cancer Res.* 2020;22(1):45.

105. André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Ann Oncol.* 2021;32(2):208-17.

106. Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, et al. PI3K-p110 $\alpha$  mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. *Oncogene.* 2016;35(27):3607-12.

107. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijnmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell.* 2007;12(4):395-402.

108. Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. *Breast Cancer Res Treat.* 2018;171(2):371-81.

109. Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, et al. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. *Breast Cancer Res Treat.* 2015;150(1):157-67.

110. Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. *Clin Cancer Res.* 2014;20(7):1935-45.

111. Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, et al. A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. *Clin Cancer Res.* 2021;27(14):3867-75.

112. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. *J Clin Oncol.* 2011;29(23):3126-32.

113. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. *Lancet Oncol.* 2015;16(7):816-29.

114. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. *N Engl J Med.* 2016;375(18):1738-48.

115. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. *N Engl J Med.* 2016;375(20):1925-36.

116. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin Oncol.* 2017;35(32):3638-46.

117. Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. *Ann Oncol.* 2021;32(8):1015-24.

118. Goel S, DeCristo MJ, Watt AC, BrinJones H, Scneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. *Nature.* 2017;548(7668):471-5.

119. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. *Cancer Cell.* 2016;29(3):255-69.

120. Prat A, Chaudhury A, Solovieff N, Paré L, Martinez D, Chic N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. *J Clin Oncol.* 2021;39(13):1458-67.

121. Spencer S, Mark D, Koei C, Zuzana T, Moqing L, Tiera L, et al. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. *Cell Systems.* 2018;6(3):329--42.e6.

122. Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. *J Immunother Cancer.* 2019;7(1):90.

123. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. *JAMA Oncol.* 2016;2(10):1354-60.

124. Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, et al. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. *Cancer Immunol Res.* 2016;4(7):600-10.

125. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. *Lancet Oncol.* 2014;15(2):e58-68.

126. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. *JAMA Oncology.* 2015;1(4):448.

127. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol.* 2010;28(1):105-13.

128. Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. *Eur J Immunol.* 2013;43(10):2718-29.

129. Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, et al. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncol.* 2018;4(11):e181564.

130. Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S. Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. *Cancers (Basel).* 2021;13(23).

131. Dieci MV, Miglietta F, Guarneri V. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. *Cells.* 2021;10(2).

132. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cell Mol Immunol.* 2020;17(8):807-21.

133. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2012;13(1):25-32.

134. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncol.* 2014;15(10):1137-46.

135. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol.* 2013;24(9):2278-84.

136. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol.* 2014;25(8):1544-50.

137. Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, et al. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. *Ann Oncol.* 2019;30(4):575-81.

138. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. *JAMA Oncol.* 2016;2(1):56-64.

139. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, et al. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. *Clin Cancer Res.* 2016;22(23):5729-37.

140. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, et al. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. *JAMA Oncol.* 2020;6(10):1598-605.

141. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. *Breast Cancer Res Treat.* 2018;167(3):671-86.

142. Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, et al. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). *Oncologist.* 2019;24(11):1439-45.

143. Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2(+) breast cancer: Current landscape and future perspectives. *Cancer Treat Rev.* 2017;61:107-15.

144. Ayoub NM, Al-Shami KM, Yaghan RJ. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. *Breast Cancer (Dove Med Press).* 2019;11:53-69.